
Thermo Fisher Scientific (TMO) Stock
Global leader in laboratory instruments and research supplies. Here's the price, business snapshot, and what's worth knowing about Thermo Fisher Scientific in November 2026.
Thermo Fisher Scientific (TMO) is a global leader in laboratory instruments, consumables, and services that support scientific research, healthcare, and industrial applications. With a diversified portfolio across life‑sciences research tools, analytical instruments, specialty diagnostics and laboratory services, the company benefits from recurring consumables and service revenue as well as long‑term demand driven by R&D, healthcare spending and public health needs. Its scale and distribution reach help it serve pharmaceutical, biotech, academic and clinical customers worldwide. Investors should note strengths such as a broad product mix, exposure to steady R&D trends and potential margin resilience from high‑margin consumables, but also risks including integration of acquisitions, regulatory scrutiny, and sensitivity to capital spending cycles. Market cap and valuation can fluctuate; this summary is educational and not personal investment advice. Consider how the company fits your risk profile and investment horizon before making decisions.
Why It’s Moving

Thermo Fisher Advances Vaccine Production Tech as CEO Prepares for Key Investor Dialogue
- Launched Gibco™ VaxEvo™ CD 293 Medium, a chemically defined solution aimed at supporting suspension HEK293 cell growth and high-titer adenovirus production from early development through scale-up.
- CEO Marc N. Casper is scheduled to participate in a fireside chat hosted by UBS on November 19, 2026, providing direct insight into company strategy for key market participants.
- The new medium is available in liquid and AGT formats, addressing evolving workflows for vaccine developers and reinforcing Thermo Fisher's role as a critical infrastructure provider in life sciences.

Thermo Fisher Advances Vaccine Production Tech as CEO Prepares for Key Investor Dialogue
- Launched Gibco™ VaxEvo™ CD 293 Medium, a chemically defined solution aimed at supporting suspension HEK293 cell growth and high-titer adenovirus production from early development through scale-up.
- CEO Marc N. Casper is scheduled to participate in a fireside chat hosted by UBS on November 19, 2026, providing direct insight into company strategy for key market participants.
- The new medium is available in liquid and AGT formats, addressing evolving workflows for vaccine developers and reinforcing Thermo Fisher's role as a critical infrastructure provider in life sciences.
Six-Month Growth Performance
When is the next earnings date for Thermo Fisher Scientific (TMO)?
Thermo Fisher Scientific has not yet confirmed a specific date for its next earnings release. Based on the company's historical reporting pattern, which typically follows a quarterly cadence with reports issued approximately three months after the previous quarter's close, the upcoming announcement is expected in late January 2027. This report will cover financial results for the fourth quarter of fiscal year 2026. Investors should monitor official corporate communications for the precise scheduling details as they become available.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Thermo Fisher Scientific's stock, expecting it to rise in value soon.
Financial Health
Thermo Fisher Scientific is performing well with strong profits, cash flow, and revenue growth.
Dividend
Thermo Fisher Scientific's dividend yield of 0.26% is below average, indicating limited income from dividends. If you invested $1000, you would be paid $2.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Consumables Revenue
Consumables and reagents can create predictable revenue and support margins, though demand can vary with research funding and market cycles.
Global Scientific Reach
A broad international footprint serves diverse customers from pharma to academia, offering resilience but also exposure to regional regulation and economic shifts.
Innovation and Scale
Product innovation and acquisitions expand the addressable market, yet integration and execution risks can affect near‑term results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.